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F.E.B.May@ncl.ac.ukAbstractThe stratification of breast cancer patients for endocrine therapies by oestrogen or
progesterone receptor expression is effective but imperfect. The present study aims were
to validate microarray studies that demonstrate TFF3 regulation by oestrogen and its
association with oestrogen receptors in breast cancer, to evaluate TFF3 as a biomarker of
endocrine response, and to investigate TFF3 function. Microarray data were validated by
quantitative RT-PCR and northern and western transfer analyses. TFF3 was induced by
oestrogen, and its induction was inhibited by antioestrogens, tamoxifen, 4-hydroxytamox-
ifen and fulvestrant in oestrogen-responsive breast cancer cells. The expression of TFF3
mRNA was associated with oestrogen receptor mRNA in breast tumours (Pearson’s
coefficientZ0.762, PZ0.000). Monoclonal antibodies raised against the TFF3 protein
detected TFF3 by immunohistochemistry in oesophageal submucosal glands, intestinal
goblet and neuroendocrine cells, Barrett’s metaplasia and intestinal metaplasia. TFF3
protein expression was associated with oestrogen receptor, progesterone receptor and TFF1
expression in malignant breast cells. TFF3 is a specific and sensitive predictive biomarker of
response to endocrine therapy, degree of response and duration of response in unstratified
metastatic breast cancer patients (PZ0.000, PZ0.002 and PZ0.002 respectively). Multi-
variate binary logistic regression analysis demonstrated that TFF3 is an independent
biomarker of endocrine response and degree of response, and this was confirmed in a
validation cohort. TFF3 stimulated migration and invasion of breast cancer cells. In
conclusion, TFF3 expression is associated with response to endocrine therapy, and
outperforms oestrogen receptor, progesterone receptor and TFF1 as an independent
biomarker, possibly because it mediates the malign effects of oestrogen on invasion
and metastasis.Key Words
" breast cancer
" trefoil factors
" progesterone receptor
" oestrogen receptor
" antioestrogensicen
.0 UEndocrine-Related Cancer
(2015) 22, 465–479IntroductionMany of the 1.7 million women diagnosed each year
with breast cancer benefit from endocrine therapy (May
2014). Introduced originally for the treatment of breast
cancer patients who present or relapse following surgerywith metastatic disease, endocrine therapy remains a
mainstay of systemic intervention (Beatson 1896, Ariazi
et al. 2006). Primary endocrine therapy is effective for
patients with inoperable disease and for frail patientssed under a Creative Commons
nported License.
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22 :3 466(Biganzoli et al. 2012). Adjuvant endocrine therapy for
early breast cancer patients became widespread in the
mid to late 1980s (Davies et al. 2013).
Two main categories of drugs target the dependence of
malignant breast epithelial cells upon oestrogens. Aroma-
tase inhibitors inhibit cytochrome P450 CYP-19, the
enzyme that converts androgens to oestrogens, and thereby
reduce circulating concentrations of tumour-promoting
oestrogens (Lonning 1998, Santen et al. 2009). Letrozole
and anastrozole, which were derived from aminoglutethi-
mide, compete reversibly with haeme (Klein et al. 1995,
Dowsett et al. 2000), whereas exemestane, which sup-
planted testolactone, competes irreversibly with the sub-
strate (Geisler et al. 1998). Antioestrogens are competitive
inhibitors of oestrogens for the oestrogen receptor, which is
a ligand-dependent transcription factor with many target
genes (May & Westley 1988, Wright et al. 2009). Tamoxifen
and raloxifene have partial agonist activity (Powles 2013),
whereas antioestrogens, such as fulvestrant, are pure
antagonists (Howell et al. 2005, Johnston & Cheung 2010).
Around 50% of advanced breast cancer patients
stratified to receive endocrine therapy based upon
evaluation of oestrogen receptor status receive no benefit
from the therapy, and some patients who are not offered
endocrine therapy could benefit from the therapy (Chang
et al. 2000, Allred 2010, Davies et al. 2011). The measure-
ment of proteins encoded by genes whose expression is
dependent upon an active oestrogen response should
distinguish malignant cells that are oestrogen responsive
and more sensitive to endocrine therapy. The detection of
the progesterone receptor, which is induced by oestrogen,
is indicative of a positive response (Horwitz et al. 1978, May
et al. 1989, Osborne et al. 2005), and the detection of HER2,
which is repressed by oestrogens, is indicative of a negative
response to endocrine therapy (Allred 2010). TFF1 is an
oestrogen-responsive gene (Masiakowski et al. 1982, May &
Westley 1986, 1988) that has utility as a marker of
hormonal response in breast cancer patients, but it has
not found widespread use (Foekens et al. 1990, Henry et al.
1990, 1991, Schwartz et al. 1991, Spyratos et al. 1994,
Soubeyran et al. 1996).
The trefoil factor family includes the small secreted
proteins TFF1, TFF2 and TFF3 (Thim & May 2005), which
are expressed in and secreted from mucus secretory
epithelia (Vestergaard et al. 2002, Samson et al. 2011).
These proteins are involved in the protection and
maintenance of healthy secretory epithelia via inter-
actions with mucins and the stimulation of cell motility
(Prest et al. 2002, Ruchaud-Sparagano et al. 2004, Thim
& May 2005). TFF1 is expressed in normal and malignanthttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great Britainbreast epithelial cells (Rio et al. 1988, Henry et al. 1991,
Piggott et al. 1991). TFF2 is expressed rarely in the breast
(May et al. 2004). TFF3 mRNA is expressed in breast
tumours and cell lines (May & Westley 1997, Poulsom
et al. 1997), and TFF3 protein is expressed in normal breast
epithelia and in a proportion of tumours (Ahmed et al.
2012). TFF3 protein expression is associated with lymph
node involvement and local metastasis, and TFF3 mRNA
expression is associated with cerebrospinal and osteo-
metastasis (Smid et al. 2006, Kannan et al. 2010, Ahmed
et al. 2012, May 2012, Magbanua et al. 2013).
Recent expression microarray analysis identified
TFF3 as one of relatively few genes whose expression is
regulated consistently by oestrogen in oestrogen-respon-
sive breast cancer cell lines (Wright et al. 2009). Further-
more, the TFF3 gene is among the top genes whose
expression correlates strongly with that of the oestrogen
receptor in large cohorts of breast cancer patients
(Gruvberger et al. 2001, West et al. 2001). The aims of
the present study were to validate the microarray analyses,
to determine the value of TFF3 as an independent
predictive biomarker of response to endocrine therapy
and to evaluate the response of breast cancer cells to TFF3.Materials and methods
Cell culture
Breast cancer cells were obtained from the American Type
Culture Collection (Manassas, VA, USA) or from their
originators. Cell lines were verified as mycoplasma-free
(MycoAlert Mycoplasma Detection kit; Lonza, Manche-
ster, UK) and authenticated by short tandem repeat
profiling at 16 loci by the LGC Standards (Middlesex,
UK). MCF-7, T47-D, ZR-75, EFM-19, EFF-3, SK-Br-3, Hs 578T,
BT-20, MDA-MB-231 and HBL-100 cells were cultured in
DMEM containing 10% FCS (May & Westley 1988) and
1 mg/ml insulin (May & Westley 1988). Cells were
discarded after the 30th passage. To measure the effects
of oestrogen, cells were cultured for 5 days in phenol red-
free DMEM containing 10% dextran-coated charcoal-
treated new-born calf serum (DCC/CS) and 1 mg/ml insulin
and then in this medium in the absence or presence of
10 nM oestradiol (E2) for 3 days (May & Westley 1986).Breast cancer cases
Ethical permission was obtained from the Joint Newcastle
Health Hospitals and University of Newcastle-upon-Tyne
Ethical Committee. Under the guidelines of the HumanPublished by Bioscientifica Ltd.
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22 :3 467Tissue Act, specific consent was not requested retro-
spectively for archived tissue collected before 2006. For
immunohistochemical analyses, 75 patients were iden-
tified who presented with symptomatic breast cancer
between 1983 and 1986. Patients had had first-line surgery
and received endocrine therapy as first-line systemic
therapy either for existing advanced disease or upon
relapse. All of the cases were invasive ductal carcinomas,
apart from three invasive lobular carcinomas and two
mucinous carcinomas. Endocrine therapy comprised of
tamoxifen, aminoglutethimide or oophorectomy. For the
validation cohort, a further 187 patients were identified
who had had first-line surgery between 1992 and 1994.
Patients were followed-up clinically for 124 months
or until death. Clinical data upon response to endocrine
therapy was evaluated using standard criteria (Therasse
et al. 2000). Response was categorised as complete
response, partial response, static disease or progressive
disease; the minimum criterion for response was disease
that did not progress for at least 6 months.RNA and protein analysis
RNA was prepared by LiCl:urea precipitation and phenol:-
chloroform extraction as described previously (May &
Westley 1986, Henry et al. 1990). RNA was analysed by
northern transfer and RT-PCR as described previously
(May & Westley 1988, Donaghue et al. 1999).
Recombinant human TFF3 was produced and purified
(May et al. 2003), and the mature protein was analysed by
ion exchange chromatography and gel filtration. Proteins
were electrophoresed on nondenaturing and denaturing
12–32% polyacrylamide gels and were stained with
Coomassie blue (May et al. 2003, Westley et al. 2005).
For western transfer analysis, proteins were transferred
to 0.2 mm PVDF membrane, incubated with TFF3 antisera,
conjugated secondary antibody and Pierce Supersignal
reagent and exposed to X-ray film. For ELISA, wells were
coated with 50 ml of 200 ng/ml peptide or 1–1000 ng/ml
protein (Westley et al. 2005). Plates were washed and
incubated sequentially with TFF3 monoclonal antibody
hybridoma supernatant or mouse IgG, followed by the
appropriate secondary antibody conjugated to alkaline
phosphatase. The reaction was visualised with P-N phenyl
phosphate (Piggott et al. 1991).Migration and invasion assays
For the migration assay, cells were plated into 16 mm-
diameter underscored wells, washed twice with PBS andhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great Britaincultured in phenol red-free DMEM containing 10%
DCC/CS for 24 h. The cell monolayer was ‘wounded’,
washed twice with PBS and cultured for 2 h in 0.5 ml
phenol red-free DMEM and 0.01% BSA. Cells were
photographed and cultured in the absence and presence
of TFF1 (Chadwick et al. 1997), TFF3 (May et al. 2003) or
EGF (First Link, Wolverhampton, UK) for up to 7 h, at
which point they were rephotographed. Cells were
transfected with antisense RNA as described previously
(de Blaquiere et al. 2009, Davison et al. 2011) and
processed for the migration assay. Twenty measurements
of each wound width were made, and the distance that the
wound edge had moved was calculated.
For the invasion assay, phenol red-free DMEM and
0.01% BSA with and without recombinant TFF3 (May et al.
2003) were added to the bottom wells of a 48-well
microchemotaxis chamber (Neuro Probe, Gaithersburg,
MD, USA). A polyvinylpyrrolidone-coated polycarbonate
membrane with 8 mm pores covered with collagen IV was
laid over the wells. Cells were cultured in withdrawal
medium for 2 days, trypsinised and allowed to recover for
1 h; then, 2.0!104 cells in phenol red-free DMEM and
0.01% BSA were placed in each upper well. Cells were
incubated at 37 8C, stained and counted (Prest et al. 2002).Antibody production
Rabbits were immunised with a 15 amino acid residue
TFF3 peptide conjugated to keyhole limpet haemocyanin.
BalbC mice were immunised with recombinant TFF3,
mixed with alum or titre max gold as adjuvant and
boosted at 2-week intervals. The titre of anti-TFF3
antibodies during the immunisation was monitored by
ELISA. Spleen cells from immunised mice were fused with
NS-1 cells and hybridomas that produce anti-TFF3
antibodies identified by ELISA. Hybridomas were cloned
by limiting dilution at least thrice.Immunohistochemistry
Whole sections of formalin-fixed, paraffin-embedded
tissue were deparaffinised, rehydrated and incubated in
0.5% hydrogen peroxide for 10 min and trypsin for 10 min
or 10 mM citrate buffer (pH 6.0) in a pressure cooker for
1 min. Endogenous biotin was blocked with the Dako
Cytomation. Sections were incubated with monoclonal
antibodies against TFF3 protein, TFF1 protein (Westley
et al. 2005), oestrogen receptor (NCL-L-ER-6F11; Leica
Biosystems, Newcastle Upon Tyne, UK) or progesterone
receptor (NCL-L-PGR-312; Leica Biosystems), secondaryPublished by Bioscientifica Ltd.
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(Vector Laboratories, Peterborough, Cambridgeshire, UK),
developed with diaminobenzidine and counterstained
with haematoxylin.Statistical analysis
Differences between expression levels and differences
between stimulation of migration or invasion were tested
by ANOVA. Results were considered to be statistically
significant if P!0.05. For the immunohistochemical
work, a histoscore that combined the percentage of
immuno-reactive malignant cells with the intensity
of the immuno-reaction was generated (Crosier et al.
2001, Ahmed et al. 2012). The statistical significance of
differences observed was analysed with SPSS Software
version 19.0 (SPSS, Inc.) by Kruskal–Wallis or Mann–
Whitney U tests, and the statistical significance of
correlations was analysed by Pearson’s correlation
or Spearman’s r correlation. The predictive value of the
biomarkers as continuous variables was tested by linear
regression and binary logistic regression analyses, and
their sensitivity and specificity were tested in a binary
classification test by c2 analysis. Multivariate analyses
were adjusted for potential confounding variables. Para-
meters were scaled, and the predictive ability of the
continuous variables was evaluated by multiple binary
logistic regression with the Wald statistic and by multiple
linear regression analysis refined by stepwise selection.Results
TFF3 regulation and association with oestrogen receptor
Expression microarray analysis (Wright et al. 2009), which
demonstrated consistent regulation of TFF1 and TFF3 but
not TFF2 in three oestrogen-responsive breast cancer cell
lines, was validated by real-time RT-PCR (Fig. 1). TFF1 and
TFF3 mRNAs were induced by oestrogen in five oestrogen-
responsive but not in two oestrogen-nonresponsive breast
cancer cell lines. Because the importance of the regulation
of TFF3 by oestrogen in breast cancer is unknown, unlike
that of TFF1, it was studied further. Oestrogen-receptor
and TFF3 mRNAs were co-expressed in six of 11 cell lines,
and neither was expressed in five of the cell lines. BT20
cells, which are known to express aberrant oestrogen
receptor but to be unresponsive to oestrogens, did not
express TFF3 mRNA. TFF3 protein was not detected in the
oestrogen-unresponsive MDA-MB-231 cells or in T-47D
cells, which expressed low levels of TFF3 mRNA. Morehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great BritainTFF3 protein was detected in ZR-75 cells and MCF-7 cells
that had been grown in the presence of oestrogen than in
those that had been grown in its absence. TFF3 expression
was not induced by tamoxifen, 4-hydroxytamoxifen or
fulvestrant, but all three antioestrogens inhibited the
induction of TFF3 by oestrogen.
The expression ofTFF3was measured next by northern
transfer and RT-PCR analysis in a panel of breast tumours.
The amount of TFF3 mRNA varied enormously; there were
high levels in ten, moderate levels in two, low levels in four
and none in two tumours (Fig. 2). There was a strong
positive association between oestrogen receptor and TFF3
mRNA expression (Pearson’s coefficientZ0.762, PZ0.000).
The results from the RT-PCR analysis agreed well with those
from the northern analysis. Despite the strong correlation
between oestrogen receptor and TFF3 mRNA expression,
the association was not absolute. For instance, there was
high expression of oestrogen receptor but not TFF3 mRNA
in tumours 2 and 7 and high expression of TFF3 but not
oestrogen receptor mRNA in tumour 3.The production and evaluation of antibodies against
human TFF3 protein
The data indicated that TFF3 merited investigation as an
oestrogen-responsive biomarker in breast cancer patients.
Antibodies were generated for immunohistochemical
analysis of TFF3 expression. TFF3 protein was chosen as
the immunogen as opposed to synthetic TFF3 peptides
because the resultant antibodies should have superior
sensitivity and specificity (Westley et al. 2005). Recombi-
nant human TFF3 protein was produced and purified to
homogeneity as evaluated by ion exchange chromato-
graphy and electrophoresis under nondenaturing and
denaturing conditions. It had the predicted molecular
mass of 6.6 kDa (May et al. 2003).
Hybridomas were generated from mice that had been
immunised with purified TFF3, and the sensitivity and
specificity of the monoclonal antibodies were evaluated
by ELISA and immunohistochemistry. The antibodies
detected less than 1 ng of human TFF3 and did not react
with TFF1 or TFF2 or with other growth factors (data not
shown). The antibodies reacted strongly with TFF3 in the
mucus secretory granules of goblet cells in human ileum
(Fig. 3). Equally strong immuno-reaction was detected
in the secretory granules of neuroendocrine cells. Less
immuno-reaction was visible in the cytoplasm of goblet
cells, and none was observed in the cytoplasm of absorptive
intestinal cells. There was no immuno-reaction with
stromal or endothelial cells. The antibodies detected TFF3Published by Bioscientifica Ltd.
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Figure 1
Oestrogen dependence of TFF3 expression in breast cancer cells. MCF-7,
T47-D, ZR-75, EFM-19, EFF-3, SK-Br-3, Hs 578T, BT-20, MDA-MB-231 (MDA-
231) and HBL-100 cells were withdrawn from hormones present in routine
culture medium and incubated in the absence (KE2) and presence of
10 nM oestradiol (CE2) (A and C), and in the absence (KA) and presence
of tamoxifen (Tam), 4-hydroxytamoxifen (OHT) or fulvestrant (Ful; D), or
they were grown in maintenance medium (B). RNA was prepared and
amplified by quantitative real-time PCR (A). RNA was prepared from cells
grown in maintenance medium, amplified with primer pairs for the
oestrogen receptor (490 bp) and TFF3 (233 bp) mRNAs, and the PCR
products were separated by gel electrophoresis on a 3% agarose gel and
stained with ethidium bromide (B). MCF-7, T-47D, ZR-75 and MDA-MB-231
cells were gown in the absence (KE2) and presence of 10 nM oestradiol
(CE2) and lysed, and protein extracts were prepared. The proteins were
transferred to PVDF membrane, and TFF3 was measured by western
transfer analysis (C). The positions of the molecular mass markers are
shown on the left, and those of TFF3 are shown on the right of the panels.
The meansGS.E.M. of at least three replicates are shown (A and D;
DP!0.05).
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22 :3 469in oesophageal submucosal glands but not in the surface
epithelium or in normal gastric mucosa. TFF3 was absent
from Brunner’s glands, but it was detected in all goblet cells
of the duodenum and throughout the intestines.
Strong immuno-reaction was detected in the cyto-
plasm of malignant breast epithelial cells of tumours that
expressed high concentrations of TFF3 mRNA (tumours 1,
3 and 15; Fig. 3). A much weaker reaction was detected in
tumours with low TFF3 mRNA concentrations (tumours 2
and 8), and there was no reaction in tumours in which
TFF3 mRNA was undetectable. These results demonstrate
excellent congruence between TFF3 mRNA and protein
expression and suggest that the anti-TFF3 protein
antibodies are specific and sensitive.http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great BritainThe expression of TFF3 in primary breast tumours and
its association with oestrogen receptor, progesterone
receptor and TFF1 expression
To evaluate the potential of TFF3 as a predictive biomarker
of response to endocrine therapy, we identified a cohort
of advanced breast cancer patients who had received
endocrine therapy without stratification. Serial sections
of the primary breast tumours were analysed by
immunohistochemistry.
TFF3 and TFF1 were detected in the cytoplasm,
whereas oestrogen and progesterone receptors were
detected in the nuclei of normal and in situ and invasive
malignant breast epithelial cells. The expression of all fourPublished by Bioscientifica Ltd.
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Figure 2
Association between oestrogen receptor and TFF3mRNAs in primary breast
tumours. RNA was prepared from primary breast tumours. Ten microgram
of breast tumour RNA were separated by gel electrophoresis and
transferred to Hybond-N membranes, and TFF3 mRNA (600 nucleotides)
was detected by hybridisation (A). The association between TFF3 mRNA
and oestrogen receptor mRNA expression in each primary tumour is
shown (B). The Pearson’s coefficient and P value are indicated on the panel.
RNAwas reverse transcribed and amplified by PCR with the primer pairs for
the oestrogen receptor (233 bp) and TFF3 (490 bp) mRNAs. The PCR
products were separated by gel electrophoresis on a 3% agarose gel and
stained with ethidium bromide (C).
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22 :3 470biomarkers was detected in some tumours, whereas none
of the biomarkers were expressed in other tumours (Fig. 4).
In some tumours, one or more of the oestrogen-responsive
proteins was expressed in the absence of detectable
oestrogen receptor expression or in the presence of low
oestrogen receptor expression, and in a few tumours, strong
oestrogen receptor expression was present with no or low
expression of the three oestrogen-responsive proteins.
TFF3 was detected in 71% of the breast tumours. There
was a strong positive correlation between TFF3 and
oestrogen receptor expression (Spearman’s rZ0.459,
PZ0.000), which is consistent with TFF3 expression being
under the control of oestrogen (Fig. 5). TFF3 expression was
higher in oestrogen receptor-positive tumours (AllredR3.0)
(Allred 2010) than it was in oestrogen receptor-negative
tumours (Mann–Whitney U test, PZ0.000).
There was a strong positive correlation between the
expression of TFF3 and the progesterone receptor (Spear-
man’s rZ0.466, PZ0.000) and between TFF3 and TFF1
(Spearman’s rZ0.756, PZ0.000), which is consistent with
the co-regulation by oestrogen of TFF3 and the other
two oestrogen-responsive biomarkers (Fig. 5). TFF3 was
higher in progesterone receptor-positive tumours as
compared to progesterone receptor-negative tumours
(Mann–Whitney U test, PZ0.001) and in TFF1-positive
tumours as compared to TFF1-negative tumours (Mann–
Whitney U test, PZ0.000).http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great BritainWe investigated if the expression of TFF1 was
associated, like TFF3, with that of the oestrogen or
progesterone receptor. There was a correlation between
TFF1 and oestrogen receptor expression (Spearman’s
rZ0.431, PZ0.000) and progesterone receptor expression
(Spearman’s rZ0.405, PZ0.001). TFF1 expression was
higher in tumours that express oestrogen receptors
(Mann–Whitney U test, PZ0.000) and progesterone
receptors (Mann–Whitney U test, PZ0.004). The associ-
ations between TFF1 and the oestrogen and progesterone
receptors were slightly weaker than those of TFF3. Lastly,
the relationship between the expression of the pro-
gesterone and oestrogen receptors was tested. Expression
of the two receptors was associated (Spearman’s rZ0.555,
PZ0.000), and expression of progesterone receptor was
higher in tumours that express oestrogen receptor than
it was in those that do not (Mann–Whitney U test,
PZ0.000). Thus, the expression of all four biomarkers is
correlated, but there is sufficient divergence to indicate
that they might provide independent predictive
information.Association between TFF3 and response to endocrine
therapy
Almost half of the patients responded to endocrine
therapy. Of the tumours illustrated in Fig. 4, a completePublished by Bioscientifica Ltd.
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22 :3 471response was obtained for two patients (A and C), one had
static disease (D), and there was no response for two (B and E).
TFF3 expression was higher in the tumours of women
who responded to endocrine therapy than in those of
women who received no benefit (PZ0.000, Mann–
Whitney U test, ZZK4.940) (Fig. 6). TFF3 expression wasA
B
C
Oesophagus
Breast tumour 1 Breast tumour 2 Breast tumou
H&E
H&E
TFF3
TFF3
TFF3
TFF3
TFF3
TFF3
H&E
H&E
H&E
H&E
Gastric antrum Duodenum
IgGH&E TFF3 antibod
Figure 3
Immunohistochemical validation of the antibodies against human TFF3
protein. Sections of human ileum (A), oesophagus, gastric antrum,
duodenum, jejunum, and colon (B) and of primary breast tumours (C) were
stained with haematoxylin and eosin or processed for
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great Britainassociated with the degree of response (Kruskal–Wallis II
test PZ0.000); patients with stable disease or partial
response had TFF3 expression that was intermediate
between those that did not respond and those with a
complete response. The median value of TFF3 was
considerably higher (500-fold) in patients with a completer 3 Breast tumour 8 Breast tumour 15
TFF3
TFF3
TFF3
TFF3
H&E
H&E
H&E
H&E
Jejunum Colon
y 1 TFF3 antibody 2 TFF3 antibody 3
immunohistochemistry with antibodies against mouse IgG or TFF3 as
indicated. The original magnifications for the photomicrographs were
!100 (A and C),!200 (B) and !400 for the inserts in (A). A full colour
version of this figure is available at http://dx.doi.org/10.1530/ERC-15-0129.
Published by Bioscientifica Ltd.
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22 :3 472response than it was in patients with progressive disease.
TFF3 expression was correlated also with the duration of
response to endocrine therapy (Spearman’s rZ0.639,
PZ0.000).ERα
ERα
ERα
ERα
ERα
PgR
PgR
PgR
PgR
PgR
A
B
C
D
E
Figure 4
The expression of oestrogen receptor, progesterone receptor, TFF1
and TFF3 in breast cancers. Sections of primary breast tumours were
processed for immunohistochemistry to measure oestrogen receptor (ERa),
progesterone receptor (PgR), TFF1 and TFF3. Sections are from tumours
in which all four biomarkers were detected (A), in which none of
the biomarkers were detected (B), in which one or more of the
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great BritainOestrogen receptor, progesterone receptor and TFF1
expression were associated also with response to hormone
therapy, although to different extents (Fig. 6). Expression
was significantly higher in tumours from women whoTFF1
TFF1
TFF1
TFF1
TFF1
TFF3
TFF3
TFF3
TFF3
TFF3
oestrogen-responsive biomarkers was detected in the absence (C) or
presence (D) of low oestrogen-receptor expression and in which the
oestrogen receptor is expressed with low associated expression of
the three responsive genes (D). The original magnifications for the
photomicrographs were !200. A full colour version of this figure is
available at http://dx.doi.org/10.1530/ERC-15-0129.
Published by Bioscientifica Ltd.
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Printed in Great Britainresponded to hormone therapy than in tumours from
those who did not (oestrogen receptor: PZ0.000, Mann–
Whitney U test, ZZK3.555; progesterone receptor:
PZ0.000, Mann–Whitney U test, ZZK3.601; and TFF1:
PZ0.000, Mann–Whitney U test, ZZK4.758), but the
magnitude of the differences between those who
responded and those who did not was smaller than that
for TFF3 (Kruskal–Wallis II test PZ0.003, PZ0.001 and
PZ0.001 respectively). Levels of expression were related to
the degree of response, and the highest level of expression
for all of the biomarkers was in tumours of patients with
complete response. The expression of oestrogen receptor,
progesterone receptor and TFF1 was correlated with the
duration of response, but the correlations were weaker
than they were for TFF3.TFF3 as a biomarker of response to endocrine therapy
We evaluated the potential of TFF3 to be an effective
predictive biomarker of endocrine response by univariate
logistic regression analysis. TFF3 was a statistically
significant predictor of hormonal response (PZ0.000).
Of the biomarkers considered, TFF3 was the most effective
univariate predictor, followed by progesterone receptor
(PZ0.001), TFF1 (PZ0.002) and oestrogen receptor
(PZ0.082). Univariate analyses by binary logistic
regression analyses for the four biomarkers gave similar
results: TFF3, progesterone receptor, TFF1 and oestrogen
receptor (PZ0.001, PZ0.002, PZ0.002 and PZ0.079
respectively).
The specificity and sensitivity of the biomarkers was
investigated with a binomial classification test. TFF3 and
TFF1 expression was dichotomised at a histoscore ofO35,
and oestrogen and progesterone receptors were dichot-
omised at an Allred score of R3. TFF3 was an effective
predictor, with a sensitivity of 91% and a specificity of 79%
(c2; PZ0.000), which indicates that TFF3 has utility forFigure 5
Associations between the expression of TFF3 and the other three
biomarkers. The TFF3 histoscore in individual tumours was compared with
the expression of oestrogen receptor (A), progesterone receptor (B)
and TFF1 (C). The associations between TFF1 and oestrogen receptor (D)
and progesterone receptor (E), and those between the oestrogen and
progesterone receptors (F), are shown also. For each paired association, the
Spearman’s r and P values are indicated on the panels. For the panels on
the right, the comparators were dichotomised by Allred ofO3.0 (A, B, D, E
and F) or a histoscore ofO35 (C). The horizontal bars represent the median
values, the boxes indicate the range of the second and third quartiles of the
data and the whiskers represent the range of all the data. The circles
represent outliers of more than 1.5 times, and the stars represent extreme
values of more than 3.0 times farther from the third quartile than the
difference between the third quartile and the median.
Published by Bioscientifica Ltd.
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Figure 6
The association of TFF3, TFF1, progesterone receptor and oestrogen
receptor expression with response to hormonal therapy. TFF3 expression
(A) was compared in malignant cells in tumours from patients without
(Kve) and with (Cve) a response to endocrine therapy as well as from
patients whose disease progressed (NR), stabilized (SD) or demonstrated a
partial (PR) or complete response (CR) to endocrine therapy. Similar
analyses are shown for TFF1 (B), progesterone receptor (C) and oestrogen
receptor (D). The horizontal bars represent the median values, the boxes
indicate the range of the second and third quartiles of the data and the
whiskers represent the range of all the data. The circles represent outliers
of more than 1.5 times, and the stars represent extreme values of more
than 3.0 times farther from the third quartile than the difference between
the third quartile and the median. The associations between each
biomarker and the duration of response are shown. For each paired
association, the Spearman’s r and P values are indicated on the panels.
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endocrine therapy and which patients will not. TFF1 was
effective with a sensitivity of 90% and a specificity of 73%
(c2; PZ0.000). Oestrogen and progesterone receptors gave
sensitivities of 91 and 69% and specificities of 69 and 72%
respectively (c2; PZ0.000). Oestrogen receptor and TFF3
were the most sensitive biomarkers, and TFF3 was the
most specific biomarker.Multivariate analyses
The relative importance of TFF3 as a predictive biomarker
of endocrine response was evaluated by multivariate
binary logistic regression analysis. Amongst the clinico-
pathological features and molecular biomarkers
considered, TFF3 had the greatest ability to predict the
endocrine response (PZ0.000), followed closely by pro-
gesterone receptor (PZ0.002). None of the other factors
considered, including age, tumour size, tumour type,
oestrogen receptor or TFF1, made a significant contri-
bution to the prediction. The regression equation was:
ZZK1:196C15 ðTFF3 expressionÞ
C12 ðprogesterone receptor expressionÞ
TFF3 expression predicted the degree of response as
a univariate biomarker (PZ0.002). The ability of the
different variables to predict the degree of response was
tested by multiple linear regression analysis. TFF3
(PZ0.000) and progesterone receptor (PZ0.000) were
retained in the model as effective independent predictors
of the degree of response to endocrine therapy.
TFF3 expression predicted also response duration as
a univariate biomarker (PZ0.002). After evaluation of
the ability of the different variables to predict response
duration by multiple linear regression analysis, pro-
gesterone receptor (PZ0.005) and TFF1 (PZ0.034) were
retained as independent predictors of the length of
response to endocrine therapy.
The predictive values of TFF3, TFF1, progesterone
receptor and oestrogen receptor were investigated in
a separate cohort of patients with metastatic breast cancer.
Univariate binary logistic regression analysis demon-
strated that the biomarkers are statistically significant
predictors of hormonal response. Multivariate binary
logistic analysis showed that TFF3 was the most effective
predictive biomarker (PZ0.000). The predictive value of
the progesterone receptor was slightly higher (PZ0.001) in
the validation than it was in the discovery cohort. Thus,
the analysis of a second group of patients corroborates thehttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great Britainpotential of TFF3 to be a predictive biomarker of endocrine
sensitivity.Effects of TFF3 on migration and invasion
Invasive and metastatic cells must be able to move
through the stroma and travel to distant sites. We
investigated if the predictive ability of TFF3 might be
connected with an ability to mediate malign effects of
oestrogen on breast cancer cell migration and invasion.
TFF3 stimulated the migration of breast cancer cells in
an in vitro wounding assay (Fig. 7A). The magnitude of
migration stimulated by TFF3 was similar to the effects of
TFF1 and EGF. The motogenic effect of TFF3 was
concentration dependent (Fig. 7B). TFF3 stimulated also
the invasion of breast cancer cells through collagen IV in a
modified Boyden chamber assay (Fig. 7C). The motogenic
effects of TFF3 were abrogated by antisense RNA in cells
that express TFF3 but not in cells that do not express TFF3.Discussion
The present study validated expression microarray
analyses that identified consistent oestrogen regulation
of TFF3 mRNA in breast cancer cells and an association
between oestrogen receptor mRNA and TFF3 mRNA
expression in primary breast tumours (Gruvberger et al.
2001, West et al. 2001). Our demonstration that TFF3
protein is regulated by oestrogen and inhibited by
antioestrogens in oestrogen-responsive breast cancer
cells supports the potential of TFF3 protein as a biomarker
of oestrogen dependence. That TFF3 stimulates migration
and the invasion of breast cancer cells suggests that
removal of these effects during anti-endocrine therapy
would be beneficial to patients in whose tumour cells TFF3
is expressed under the control of oestrogens.
The antibodies produced against the correctly folded
TFF3 protein (Muskett et al. 2003) detect human TFF3 with
specificity and sensitivity. TFF3 is a secreted protein and
was detected exclusively in the cytoplasm or mucus-
secretory vesicles; there was no evidence of a nuclear
immuno-reaction, as has been reported with some
commercially available antibodies. TFF3 expression was
detected in the submucosal glands of the oesophagus and
in neuroendocrine and goblet cells throughout the small
and large intestines. TFF3 was expressed in Barrett’s
metaplasia of the oesophagus and in intestinal metaplasia
of the stomach. There was a good correlation between
breast tumour TFF3 mRNA and protein expression.Published by Bioscientifica Ltd.
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Figure 7
The effects of TFF3 on breast cancer cell motility and invasion. Monolayers
of cells were ‘wounded’ with a pipette tip (A, B and D), and incubated in
the absence (unst.) or presence of 10 ng/ml EGF or 5 mg/ml TFF1 or TFF3 for
5 h (A) or the indicated concentration of TFF3 for 7 h (B) or transfected with
antisense TFF3 RNA and incubated for 5 h (D). The distance that the
wounded edges moved was measured, and the mean distancesGS.E.M. of at
least four measurements is shown. For the invasion assay, 2.0!104 cells
were placed in the upper wells of a microchemotaxis chamber in medium
containing 0.01% BSA. Cells were left to migrate on and through 8 mmpore
polyvinylpyrrolidomemembranes covered with collagen towards the lower
wells, which contained the same medium but different concentrations of
TFF3. Cells were counted in five high-power fields from triplicate wells, and
themeansGS.E.M. are shown (C). *Cell movement is statistically significantly
higher than for unstimulated cells or lower than for cells transfected with
TFF3 siRNA (ANOVA P!0.05).
E
n
d
o
cr
in
e
-R
e
la
te
d
C
a
n
ce
r
Research F E B May and B R Westley TFF3 predicts oestrogen
responsiveness
22 :3 476
http://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great BritainTFF3 protein was expressed in the majority of the
breast tumours analysed. A strength of the present study
is that whole sections of tumour tissue, rather than small
cores of tissue, were analysed. In tumours with stronger
TFF3 expression, expression was distributed relatively
evenly throughout the tumour, whereas in other tumours,
expression was strong in some areas and undetectable
in others. The positive association between oestrogen
receptor and TFF3 expression indicates that TFF3
expression is oestrogen dependent in a majority of breast
tumours. The strong association between the expression
of TFF3 and the other two oestrogen responsive proteins
supports this contention. The close relationship between
TFF3 and TFF1 may reflect the co-ordinated expression
of the two genes from the same genomic locus; they are
separated by 55 kb. The expression of TFF3 in the absence
of oestrogen receptor expression could occur if receptor
levels were below the sensitivity of detection but sufficient
to mount an oestrogen response. The response of the
majority of tumours with this profile of expression to
hormonal therapy is consistent with this explanation.
The present study includes tumours that do not
express oestrogen or progesterone receptors, which allows
the predictive value of biomarkers to be evaluated in
tumours that are oestrogen receptor-negative or that have
relatively low levels of expression. Multivariate binary
logistical regression analysis demonstrated that the ability
of TFF3 to discriminate which patients will respond
to endocrine intervention is independent of the other
parameters evaluated. TFF3 is also an independent
predictor of the degree of response to endocrine interven-
tions. It remains possible that other variables were
excluded from the final equation because they are highly
related to TFF3. The results from the discovery cohort were
validated in an independent cohort of patients with
metastatic breast cancer.
There are three clinical settings in which the measure-
ment of TFF3 could inform the clinical management of
breast cancer patients. The first is for thew25% of patients
with oestrogen receptor- and progesterone receptor-
negative tumours. These patients are not eligible for
endocrine therapy, although around 10% would benefit
from it. Measurement of TFF3 and TFF1 would identify
patients who might respond to hormonal interventions.
The second clinical setting is for patients who have
oestrogen receptor levels around the threshold that
defines positivity, which is currently an Allred score of
3.0. There has been debate about the most appropriate
threshold and a trend to define tumours with lower
oestrogen receptor content as positive (Allred 2010);Published by Bioscientifica Ltd.
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can receive and benefit from endocrine therapy but
reduces the accuracy of prediction. Knowledge of the
expression of oestrogen-responsive biomarkers could
assist in treatment stratification, because tumours that
express TFF3, TFF1 and progesterone receptor are more
likely to respond. The corollary is that absence of
expression would indicate that endocrine intervention is
unlikely to be effective. Such knowledge might increase
patient compliance in the adjuvant setting; it is estimated
that 40–50% of patients do not take their endocrine
therapy (van Herk-Sukel et al. 2010, Hershman et al. 2010).
The third clinical setting is for patients with oestrogen
receptor-positive tumours, of whom around 50% do not
respond to endocrine therapy. The absence of pro-
gesterone receptor, TFF1 and especially TFF3 expression
in patients with oestrogen receptor-positive tumours
provides a strong indication that patients will not benefit
from hormonal therapy. Amongst the oestrogen receptor-
positive, TFF3-positive tumours, 84% responded and 68%
had a partial or complete response, whereas only 37%
of oestrogen receptor-positive, TFF3-negative tumours
responded and none had a partial or complete response.
The absence of TFF3 would provide clinicians with
additional information about likely benefit from
endocrine therapy. The incidence of oestrogen receptor-
positive breast cancer with distant metastasis at presen-
tation has risen recently by 2% annually in women below
the age of 40 and even faster in women below the age of 35
(Johnson et al. 2013). Treatment of these young women
with systemic, endocrine-based therapies should be
informed by the best possible information obtained from
analysis of combinations of biomarkers, including TFF3.
We investigated the possibility that TFF3 might be
a predictive biomarker of oestrogen responsiveness
because it mediates the effects of oestrogen on breast
cancer metastasis. Consistent with our previous study,
which showed that TFF3 is associated with lymphatic,
vascular, neural and muscle invasion in breast cancer
(Ahmed et al. 2012), TFF3 promoted cell migration and
invasion. These data suggest that hormone therapy
reduces tumour progression by inhibiting the synthesis
of proteins, such as TFF3.
In conclusion, TFF3 expression is an independent
predictive biomarker of both oestrogen response and
degree of response. The evaluation of TFF3 expression in
addition to oestrogen and progesterone receptors could
identify additional breast cancer patients who might
benefit from endocrine intervention and could inform
the clinical management of patients with low oestrogenhttp://erc.endocrinology-journals.org
DOI: 10.1530/ERC-15-0129
q 2015 The authors
Printed in Great Britainreceptor positivity. Furthermore, the absence of TFF3
expression in tumours that express oestrogen receptor
indicates that endocrine therapy is less likely to be
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